Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
1,277.50
-6.10
(-0.48%)
At close: February 28 at 3:30:01 PM GMT+5:30
Breakdown
3/31/2024
3/31/2023
Total Assets
13,086,110
20,088,080
Total Liabilities Net Minority Interest
9,128,980
12,233,550
Total Equity Gross Minority Interest
3,957,130
7,854,530
Total Capitalization
6,673,050
11,203,280
Common Stock Equity
3,957,130
7,854,530
Capital Lease Obligations
90,090
275,290
Net Tangible Assets
702,670
4,477,470
Working Capital
-4,542,070
-6,368,110
Invested Capital
9,578,770
16,221,440
Tangible Book Value
702,670
4,477,470
Total Debt
5,711,730
8,642,200
Net Debt
5,556,920
8,317,170
Share Issued
114,436.02
114,436.02
Ordinary Shares Number
114,436.02
114,436.02
3/31/2023 - 1/24/2025
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CONCORDBIO.NS Concord Biotech Limited
1,501.00
-5.56%
BCAX Bicara Therapeutics Inc.
13.30
+7.61%
RLYB Rallybio Corporation
0.7223
-2.39%
IMTX Immatics N.V.
4.3800
0.00%
ENSC Ensysce Biosciences, Inc.
5.39
+2.67%
PTGX Protagonist Therapeutics, Inc.
37.59
+3.44%
SION Sionna Therapeutics, Inc.
13.77
-6.71%
NKTR Nektar Therapeutics
0.8500
+6.76%
RIGL Rigel Pharmaceuticals, Inc.
23.06
+5.88%
ALLO Allogene Therapeutics, Inc.
1.9500
0.00%